Camoquine
Camoquine - General Information
A 4-aminoquinoquinoline compound with anti-inflammatory properties.
Pharmacology of Camoquine
Camoquine, a 4-aminoquinoline similar to chloroquine in structure and activity, has been used as both an antimalarial and an anti-inflammatory agent for more than 40 years. Camoquine is at least as effective as chloroquine, and is effective against some chloroquine-resistant strains, although resistance to amodiaquine has been reported. The mode of action of amodiaquine has not yet been determined. 4-Aminoquinolines depress cardiac muscle, impair cardiac conductivity, and produce vasodilatation with resultant hypotension. They depress respiration and cause diplopia, dizziness and nausea.
Camoquine for patients
Camoquine Interactions
Camoquine Contraindications
Because amodiaquine may concentrate in the liver, the drug should be used with caution in patients with hepatic disease or alcoholism, and in patients receiving hepatotoxic drugs.
Additional information about Camoquine
Camoquine Indication: For treatment of acute malarial attacks in non-immune subjects.
Mechanism Of Action: The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Amodiaquine
Synonyms: Amodiaquin; Amodiaquine USP24; Amodiaquine, ring-closed
Drug Category: Amebicides; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials
Drug Type: Small Molecule; Approved
Other Brand Names containing Amodiaquine: Basoquin; CAM-AQ1; CAM-AQI; Camochin; Camoquin; Camoquin HCL; Camoquinal; Camoquine; Flavoquin; Flavoquine; Miaquin;
Absorption: Rapidly absorbed following oral administration.
Toxicity (Overdose): LD50 (mouse, intraperitoneal) 225 mg/kg, LD50 (mouse, oral) 550 mg/kg. Symptoms of overdose include headache, drowsiness, visual disturbances, vomiting, hypokalaemia, cardiovascular collapse and cardiac and respiratory arrest. Hypotension, if not treated, may progress rapidly to shock. Electrocardiograms (ECG) may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, broadening of the QRS complex, and progressive bradycardia leading to ventricular fibrillation and/or arrest.
Protein Binding: Not Available
Biotransformation: Hepatic biotransformation to desethylamodiaquine (the principal biologically active metabolite) is the predominant route of amodiaquine clearance with such a considerable first pass effect that very little orally administered amodiaquine escapes untransformed into the systemic circulation.
Half Life: 5.2 ± 1.7 (range 0.4 to 5.5) minutes
Dosage Forms of Camoquine: Not Available
Chemical IUPAC Name: 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
Chemical Formula: C20H22ClN3O
Amodiaquine on Wikipedia: https://en.wikipedia.org/wiki/Amodiaquine
Organisms Affected: Plasmodium
